Page last updated: 2024-09-27

2-(4-hydroxyphenyl)-4,5-diphenylimidazole

Cross-References

ID SourceID
PubMed CID352144
CHEMBL ID390388
SCHEMBL ID252964
MeSH IDM0482815

Synonyms (37)

Synonym
4-(4,5-diphenyl-1h-imidazol-2-yl)phenol
EU-0047402
nsc683642
OPREA1_873701
1752-94-9
nsc-525164
nsc525164
nsc-683642
OPREA1_149383 ,
SR-01000511510-2 ,
4-(4,5-diphenyl-2-imidazolyl)phenol, suitable for chemiluminescence, >=99.0% (hplc)
CHEMBL390388
AKOS000579005
4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)cyclohexa-2,5-dien-1-one
D4178
2-(4-hydroxyphenyl)-4,5-diphenylimidazole
4-(4,5-diphenyl-2-imidazolyl)phenol
SCHEMBL252964
JMBUODONIOAHPZ-UHFFFAOYSA-N
DTXSID50419769
ck967
4-(4,5-diphenyl-4-imidazolin-2-ylidene)cyclohexa-2,5-dien-1-one
bdbm67466
cid_5385986
4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)-1-cyclohexa-2,5-dienone
sr-01000511510
SR-01000511510-1
AS-65383
J-011105
mfcd00740542
4-(4,5-diphenyl-1h-imidazol-2-yl)phenol [for biochemical research]
2-(4-hydroxyphenyl)-4,5-diphenylimidazol
phenol, 4-(4,5-diphenyl-1h-imidazol-2-yl)-
BAA75294
CS-W009425
HY-W008709
Z60248806

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NADPH oxidase 1Homo sapiens (human)IC50 (µMol)17.00000.04401.26095.5000AID2808
Oligo-1,6-glucosidase IMA1Saccharomyces cerevisiae S288CIC50 (µMol)97.12009.37009.37009.3700AID1800999
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1389179Inhibition of electric eel AChE at 10 uM using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID284328Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1389182Antioxidant activity in brain homogenate (unknown origin) assessed as decrease in TBARS formation by UV-visible spectrophotometric method2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID1335178Antimalarial activity against chloroquine-resistant asexual erythrocyte stage of Plasmodium falciparum K1 infected in human type O+ erythrocytes assessed as growth inhibition incubated for 48 hrs by NBT dye based LDH release assay2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against
AID284330Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 30 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284333Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284331Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 60 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284338Antiinflammatory activity assessed as reduction of carrageenan-induced paw volume in intraperitoneally dosed Wistar rat after 3 hrs2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284332Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 120 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1389178Inhibition of equine serum BChE at 10 uM using S-butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID284336Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 60 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284329Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 15 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1335175Inhibition of beta-hematin formation incubated for 5 to 6 hrs by NP40 detergent-mediated assay2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against
AID284337Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 120 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284334Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 15 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284335Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 30 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1335177Antimalarial activity against chloroquine-sensitive asexual erythrocyte stage of Plasmodium falciparum NF54 infected in human type O+ erythrocytes assessed as growth inhibition incubated for 48 hrs by NBT dye based LDH release assay2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against
AID1800999Alpha-glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2014.11.006: \\Organocatalyzed solvent free an efficient novel synthesis of 2,4,5-trisubstituted imidazoles for a-glucosidase inhibition to treat diabetes.\\2015Bioorganic chemistry, Feb, Volume: 58Organocatalyzed solvent free an efficient novel synthesis of 2,4,5-trisubstituted imidazoles for α-glucosidase inhibition to treat diabetes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]